MARKET

NVTA

NVTA

Invitae
NYSE

Real-time Quotes | Nasdaq Last Sale

31.54
+1.80
+6.05%
After Hours: 30.82 -0.72 -2.28% 19:59 09/17 EDT
OPEN
30.10
PREV CLOSE
29.74
HIGH
31.58
LOW
29.77
VOLUME
5.21M
TURNOVER
--
52 WEEK HIGH
61.59
52 WEEK LOW
24.16
MARKET CAP
6.85B
P/E (TTM)
-14.7618
1D
5D
1M
3M
1Y
5Y
Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director
CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team...
GlobeNewswire · 3d ago
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Sept. 10, 2021: VCYT, CRSP, SPFR, MKFG, RPTX, NVTA, PSNL, ADPT
Veracyte (VCYT) - 45,484 CRISPR Therapeutics (CRSP) - 17,000  Jaws Spitfire Acquisition Corp (SPFR) - 318482 Markforged Holding Corp (MKFG) - 174,225  Repare Therapeutics (RPTX)
Benzinga · 4d ago
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Sept. 8, 2021: PATH, NVTA, FATE, PD, DE, MKFG, KMTUY, SPFR, ROKU, SPLK, KVSB, ADPT, SLGC, VCYT, PSNL, RPTX, ETSY, FTCH, STNE, Z, JD, HEI, BLDE, AVAV
UiPath (PATH) - 1,382,967 Shares Invitae (NVTA) - 616,413 Fate Therapeutics (FATE) - 129,739 PagerDuty (PD) - 55,058 Deere & Co (DE) - 37,991 Markforged (MKFG) - 600,664 Komatsu (KMTUY) - 96,118 Jaws
Benzinga · 09/09 13:58
Invitae Strengthens Health Data Platform With Ciitizen Acquisition
Benzinga · 09/07 15:01
Invitae to Acquire Consumer Health Tech Company Ciitizen in $325 Million Deal
MT Newswires · 09/07 07:59
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, Sept. 2, 2021: FATE, KMTUY, BLDE, MKFG, NNDM, KTOS, NIU, SPFR, GENI, VEEV, PFE, NVTA, PSNL, JD, PDD, Z, TDOC, PRNT
Fate Therapeutics (FATE) - 148,263 Shares Komatsu (KMTUY) - 189,578 Blade Air Mobility (BLDE) - 370,118 Markforged (MKFG) - 259,540 Nano Dimension (NNDM) - 197,145 Kratos Defense & Security Solutions (KTOS) -
Benzinga · 09/03 13:14
Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
/PRNewswire/ --  (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual fireside chat at the Morgan Stanley 19 Annual Global Healthcare Conference on , at .
PR Newswire - PRF · 09/01 11:30
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Aug. 30, 2021: SGFY, FATE, VCYT, ACIC, DDD, NNDM, MKFG, KTOS, NIU, BLDE, SPFR, PTON, GENI, PFE, NVTA, DYNS, QSI, ADPT, PSNL, RPTX
Signify Health (SGFY) - 418,845 Fate Therapeutics (FATE) - 89,825 Veracyte (VCYT) - 3,391 Atlas Crest Investment Corp (ACIC) - 860,704 3D Systems (DDD) - 138,600 Nano Dimensions (NNDM)
Benzinga · 08/31 14:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVTA. Analyze the recent business situations of Invitae through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVTA stock price target is 40.44 with a high estimate of 58.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 443
Institutional Holdings: 199.33M
% Owned: 91.71%
Shares Outstanding: 217.34M
TypeInstitutionsShares
Increased
147
22.30M
New
59
3.60M
Decreased
102
14.80M
Sold Out
61
3.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Eric Aguiar
President/Chief Executive Officer/Co-Founder/Director
Sean George
Chief Financial Officer
Yafei Wen
Chief Operating Officer
Kenneth Knight
Chief Accounting Officer
Robert Werner
General Counsel/Secretary
Thomas Brida
Other
Robert Nussbaum
Other
Katherine Stueland
Other
Karthik Suri
Independent Director
Geoffrey Crouse
Independent Director
Christine Gorjanc
Independent Director
Kimber Lockhart
Independent Director
Chitra Nayak
No Data
About NVTA
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Webull offers kinds of Invitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVTA stock methods without spending real money on the virtual paper trading platform.